Lincoln Pharmaceuticals
LINCOLNNSE

Lincoln Pharmaceuticals

₹590.00-16.20 (2.67%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
586.40
Today’s high
620.00
52 week low
440.00
52 week high
770.00
Open price
620.00
Previous close
606.20
Live volume
1,78,985
Lower circuit
472.00
Upper circuit
708.00

Fundamentals

Market Cap
₹1,225Cr
ROE
11.60%
P/E Ratio(TTM)
13.93
EPS(TTM)
43.88
P/B Ratio
1.62
Dividend Yield
0.29%
Industry P/E
33.73
Book Value
378.25
Debt to Equity
0.01
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
MAR '26
Revenue (Cr)
₹183
+0.89%
Profit (Cr)
₹11.63
-59.34%
050100150200
Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Revenue growthValue
1Y (TTM)+14%
3Y CAGR+10%
Profit growthValue
1Y (TTM)0%
3Y CAGR+6%

About

Established in 1979, Lincoln Pharmaceuticals has carved a distinct niche in the global pharmaceutical landscape, committed to innovation, quality, and expansion. The company envisions a world where innovative treatments conquer diseases, aiming to be a leading force in global healthcare by revolutionizing medicine through relentless research. Central to its operations is a singular mission to transform healthcare globally by relentlessly pursuing groundbreaking medicines through focused research and development. It specializes in a diverse product portfolio that includes tablets, capsules, dry syrups, liquid vials, injectables, and ointments to address various medical needs. The company is also expanding its portfolio into lifestyle and chronic segments, with a particular focus on women's healthcare and dermatology. With a robust global footprint, the company exports its pharmaceutical products to over 60 countries and plans to expand to 90 countries in the next 2-3 years.;
CEO/MD
Mr. Mahendra G. Patel
Founded in
1979
NSE symbol
LINCOLN

Shareholding Pattern

Mar '25
Jun '25
Sep '25
Dec '25
Mar '26
Promoters
49.78%
Retail And Others
43.94%
Foreign Institutions
5.19%
Other Domestic Institutions
1.08%
Livesquawk
Lincoln Pharma's Q4 EBITDA declined to ₹248M from ₹267M YoY. EBITDA margin dropped to 13.3% from 15.9% YoY.
Livesquawk
Lincoln Pharma's Q3 revenue rose to 1.66B INR from 1.47B INR YoY.
2026
28
May
Quarterly & Annual Result
Release date
12
Feb
Quarterly Result
Release date
2025
13
Nov
Quarterly Result
Release date

12
Sep
Dividend
Ex date
₹1.80
per share

For each share you hold, you will receive ₹1.80
Dividend amount₹1.80 per share
Dividend TypeFinal
Ex Date12 Sep ‘25
Record Date12 Sep ‘25
Announcement date22 May ‘25
7
Aug
Quarterly Result
Release date

22
May
Dividend
Announced
₹1.80
per share

For each share you hold, you will receive ₹1.80
Dividend amount₹1.80 per share
Dividend TypeFinal
Ex Date12 Sep ‘25
Record Date12 Sep ‘25
Announcement date22 May ‘25
2024

13
Sep
Dividend
Ex date
₹1.80
per share

For each share you hold, you will receive ₹1.80
Dividend amount₹1.80 per share
Dividend TypeFinal
Ex Date13 Sep ‘24
Record Date14 Sep ‘24
Announcement date16 May ‘24
Events calendar
View upcoming events in other stocks